News | October 08, 2009

Philips to Apply Digital Silicon Photomultipliers to Medical Imaging

October 8, 2009 - Royal Philips Electronics said it has developed a digital silicon photomultiplier technology that will allow faster and more accurate photon (the basic quantum unit of light) counting in a wide range of applications where ultra-low light levels need to be measured.

Areas where the new technology could have a major impact include medical imaging, in particular positron emission tomography (PET), and in-vitro diagnostic tests such as DNA sequencing and protein/DNA microarrays. Other relevant areas include high-energy physics, night-vision systems and other applications that currently use light detectors that are based on so-called photomultiplier tubes.

As with virtually all ‘solid-state’ alternatives, this new digital silicon photomultiplier technology should enable the production of smaller and lighter battery-powered equipment for use in areas such as medical diagnostics and surveillance. The key to the technology lies in its ability to combine high-quality single-photon detectors (silicon avalanche photodiodes) with low-voltage CMOS logic on the same silicon substrate. Moreover, these new silicon photomultipliers can be manufactured using a conventional CMOS process technology.

The performance of Philips’ prototype detector, in terms of its speed and dark count level (background noise), will be presented at the IEEE Nuclear Science Symposium and Medical Imaging Conference, which will take place on October 25-31 in Orlando, Fla. Other important features of this new light detection technology include its robustness, low power consumption, light detection efficiency, and very high level of integration of the optical detection and associated electronic components.

“Solid-state digital technology has already taken over from outdated analog solutions in every-day applications such as TVs, camcorders and photography,” says Rob Ballizany, vice president of Philips Corporate Technologies and responsible for the commercialization of this new technology. “...high-end professional applications such as medical imaging will undergo a similar switch to digital detectors in the next few years.”

For more information: www.medical.philips.com

Related Content

Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows).

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.

News | Prostate Cancer | March 07, 2018
An Italian study featured in the March i
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...